🔗 Share this article

A shadow market for unlicensed weight-loss drugs is being driven by TikTok fitness influencers and sellers on messaging platforms, according to recent findings.

Experimental Drug Gaining Traction Online

Retatrutide, which is still in research studies, is being advertised by social media influencers for its supposed fat-burning properties. Followers are urged to message these profiles directly for supplier links, while also obtaining discount codes.

Active Commerce on Social Networks

Separately, a flourishing market exists on Telegram, where communities with numerous of participants share “before and after” images, administration instructions and claims of rapid British shipping. Sellers promote the substance there before redirecting customers to other platforms for purchases.

Understanding Retatrutide

This medication is an experimental injectable developed by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies suggest it could help patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Healthcare Experts Express Worries

However, physicians and pharmacists have cautions that the distribution of what remains an unapproved medication in the United Kingdom is a cause for concern and could result in individuals injecting products of unknown origin.

Several professionals said the demand for the experimental drug could be linked to the rising cost of licensed slimming treatments such as Mounjaro.

Legal Position and Enforcement

Marketing the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unapproved medication that must not be marketed or supplied for human use under the Human Medicines Regulations 2012.

Several influencers attempt to circumvent the regulations by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still breach pharmaceutical, marketing, and customer laws, potentially leading to penalties, prosecution or prison.

Platform Response and Material Removal

Based on the social media company, the service has taken down problematic content and banned related hashtags and query recommendations. The organization stated it was dedicated to maintaining the platform secure and investing in strengthening compliance measures.

Online Marketplace Operations

Investigations also discovered communities with up to nine thousand participants marketing retatrutide using the platform's built-in discovery tool, which functions like a public directory. Entering “retatrutide” immediately displays groups with thousands of members, filled with photos of slimming results, glowing testimonials and detailed guides for preparing or injecting at home.

After minutes of joining one community, a seller shared WhatsApp details, where the majority of purchases take place. The seller sent an guidebook and promised shipping within two days. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. Not one inquired about weight, health issues or previous experience.

Item Details and Costs

Within these communities, messages display black plastic parcels with postal service labels, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Customers can choose between powder vials, prepared at residence with purified liquid, or ready-to-use pens typically priced at 160 pounds for 20mg. When asked how long a pen should last, sellers give contradictory responses ranging from a several days to “depends on your body”.

Service Moderation and Security Actions

A representative for the messaging service said it actively moderated dangerous material on its service including content that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are administering materials they cannot confirm. Although the science behind retatrutide is sound, these digital versions may not include what they advertise,” said Jason Murphy, the head of pharmacy at a pharmacy service.

A medical professional of an online medical service connected the increase in demand to current price rises for authorized slimming drugs such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But counterfeit injections are extremely dangerous. You can’t be certain what’s inside or whether the conditions they were made in was clean,” she explained.

Her team has already encountered individuals harmed by self-injection from unconfirmed suppliers. “We recognize the frustration, but purchasing from messaging apps or communication platforms is taking chances with your well-being,” said the doctor. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Position

A spokesperson from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any government authority globally. “Therefore at this point no one can market [it] for human use,” they said, adding that any item “misleadingly claiming itself as a Lilly investigational substance not yet approved … may expose users to potentially significant health risks”.